Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$7.34 USD
+0.27 (3.82%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $7.32 -0.02 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 101 - 120 ( 131 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Commercial Biotech Preview: Getting The Ducks In A Row
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pegtibatinase PoC Data Looks Solid, As Nefecon Gains FDA Nod in IgAN
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Steady As She Goes, While IgAN Next Steps Draw Closer
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Commercial Biotech Preview: Will We See Tricks or Treats in 3Q21 Earnings?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vifor Takes the Reigns In Europe - Sparsentan Commercialization Agreement
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA, TVTX Agree on Path Forward For FSGS/Sparsentan
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PROTECTing The Sparsentan Franchise - PROTECT Meets Primary Endpoint
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to Neutral; Arguing Balls and Strikes Won''t Change the Outcome
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Selloff Overdone In Our View - Continue To Hold Positive Bias
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pushing Forward Towards PROTECT - Next Readout On Track For 3Q21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Commercial Biotech Preview: Are We In A Bear Market?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L